FACTORS INFLUENCING THE DEVELOPMENT OF MULTI DRUG-RESISTANT TUBERCULOSIS: LITERATURE REVIEW
Abstract
Tuberkulosis resisten obat (TB-MDR) adalah tantangan besar dalam pengendalian TB global, disebabkan oleh strain Mycobacterium tuberculosis yang resisten terhadap antibiotik lini pertama, isoniazid dan rifampisin. Menurut WHO, pada tahun 2024 diperkirakan terdapat 400.000 kasus TB-MDR di dunia. Tinjauan literatur ini bertujuan menganalisis faktor-faktor sosio-demografi, komorbiditas, gaya hidup, dan kebijakan yang memengaruhi kejadian TB-MDR, dengan meninjau 20 penelitian di Afrika, Asia, Eropa, Australia, dan Amerika. Penelitian ini menggunakan pendekatan meta-analisis untuk mengidentifikasi faktor risiko, termasuk ketidakpatuhan minum obat, riwayat komorbid DM, riwayat komorbid HIV, dan usia produktif. Temuan ini menekankan pentingnya intervensi masyarakat untuk kelompok berisiko, peningkatan kepatuhan pengobatan, dan penguatan program pengendalian TB. Diperlukan kebijakan berbasis bukti untuk skrining dini dan tata laksana terpadu, serta model intervensi yang adaptif. Penelitian lanjutan disarankan untuk mengevaluasi peran pendekatan komunitas dan inovasi digital dalam meningkatkan keberhasilan pengobatan.
Full text article
Generated from XML file
References
1. World Health Organization WHO. Global Tuberculosis Report. WHO; 2023. https://www.who.int/publications/i/item/9789240083851
2. World Health Organization. Drug Resistant TB. WHO. 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024/tb-disease-burden/1-3-drug-resistant-tb?
3. Ladha N, Bhardwaj P, Chauhan NK, Naveen KHS, Nag VL, Giribabu D. Determinants, risk factors and spatial analysis of multi-drug resistant pulmonary tuberculosis in Jodhpur, India. Monaldi Arch Chest Dis. 2022;92(4). doi:10.4081/monaldi.2022.2026
4. Abebe G, , Zegeye Bonsa WK. Treatment Outcomes and Associated Factors in Tuberculosis Patients at Jimma University Medical Center: A 5‑Year Retrospective Study Gemeda. Int J Mycobacteriology. 2017;6(3):239-245. doi:10.4103/ijmy.ijmy
5. de Dieu Longo J, Woromogo SH, Tekpa G, et al. Risk factors for multidrug-resistant tuberculosis in the Central African Republic: A case-control study. J Infect Public Health. 2023;16(9):1341-1345. doi:10.1016/j.jiph.2023.06.007
6. Ma JB, Zeng LC, Ren F, et al. Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study. Infect Drug Resist. 2022;15(August):4947-4957. doi:10.2147/IDR.S376177
7. Russom M, Tesfaselassie H, Goitom R, et al. Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study. Tuberc Res Treat. 2019;2019:1-6. doi:10.1155/2019/9429213
8. Baya B, Achenbach CJ, Kone B, et al. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Published online 2019:149-155. doi:10.1016/j.ijid.2019.02.004.Clinical
9. Saifullah A, Mallhi TH, Khan YH, et al. Evaluation of risk factors associated with the development of MDR-and XDR-TB in a tertiary care hospital: A retrospective cohort study. PeerJ. 2021;9:1-19. doi:10.7717/peerj.10826
10. Kizito E, Musaazi J, Mutesasira K, et al. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. BMC Infect Dis. 2021;21(1):1-7. doi:10.1186/s12879-021-05967-2
11. Elduma AH, Mansournia MA, Foroushani AR, et al. Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: A case-control study. Epidemiol Health. 2019;41:1-9. doi:10.4178/EPIH.E2019014
12. Admassu F, Abera E, Gizachew A, Sedoro T, Gari T. Risk factors of multidrug resistant tuberculosis among patients with tuberculosis at selected multidrug resistance treatment initiative centres in southern Ethiopia: A case-control study. BMJ Open. 2023;13(1):1-6. doi:10.1136/bmjopen-2022-061836
13. Tenzin C, Chansatitporn N, Dendup T, et al. Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: A nationwide case-control study. PLoS One. 2020;15(7 July):1-13. doi:10.1371/journal.pone.0236250
14. Soares VM, de Almeida IN, Figueredo LJ de A, et al. Factors associated with tuberculosis and multidrug-resistant tuberculosis in patients treated at a tertiary referral hospital in the state of Minas Gerais, Brazil. J Bras Pneumol. 2020;46(2):1-8. doi:10.36416/1806-3756/e20180386
15. Hirama T, Sabur N, Derkach P, et al. Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016. Canada Commun Dis Rep. 2020;46(04):84-92. doi:10.14745/ccdr.v46i04a05
16. Yao S, Yan J, Li L, et al. Determining mycobacterium tuberculosis drug resistance and risk factors for multidrugresistant tuberculosis in sputum smear-positive tuberculosis outpatients in Anhui province, China, 2015–2016. Infect Drug Resist. 2020;13:1023-1032. doi:10.2147/IDR.S244482
17. Wang Z, Hou Y, Guo T, et al. Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China. Front Public Heal. 2023;11. doi:10.3389/fpubh.2023.1117101
18. Camphor HS, Viney K, Polkinghorne B, Pennington K. Retrospective analysis of multidrug-resistant tuberculosis case notifications in Australia (1999-2018). Commun Dis Intell. 2020;44. doi:10.33321/cdi.2020.44.68
19. Carter BB, Zhang Y, Zou H, et al. Survival analysis of patients with tuberculosis and risk factors for multidrug-resistant tuberculosis in Monrovia, Liberia. PLoS One. 2021;16(4 April):1-13. doi:10.1371/journal.pone.0249474
20. Montalvo-Otivo R, Ramírez-Breña M, Bruno-Huamán A, Damián-Mucha M, Vilchez-Bravo S, Quisurco-Cárdenas M. Distribución geográfica y factores de riesgo de tuberculosis multidrogorresistente en el centro de Perú. Rev la Fac Med. 2020;68(2):245-251. doi:10.15446/revfacmed.v68n2.71715
21. Aderita NI, Murti B, Suryani N. Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Ngawi, Indonesia. J Epidemiol Public Heal. 2016;1(2):86-99.
22. Wotale TW, Lelisho ME, Negasa BW, Tareke SA, Gobena WE, Amesa EG. Identifying risk factors for recurrent multidrug resistant tuberculosis based on patient’s record data from 2016 to 2021: retrospective study. Sci Rep. 2024;14(1):23912. doi:10.1038/s41598-024-73209-x
23. Chuchottaworn C, Thanachartwet V, Sangsayunh P, et al. Risk factors for multidrug-resistant tuberculosis among patients with pulmonary tuberculosis at the central chest institute of Thailand. PLoS One. 2015;10(10):1-17. doi:10.1371/journal.pone.0139986
24. Afrina Y. Faktor Lingkungan Dengan Kejadian Tuberculosis Paru. J Ris Kesehat Poltekkes Depkes Bandung. 2023;15(1):1-21. file:///C:/Users/ACER/Downloads/2105-Article Text-8372-1-10-20230204.pdf
25. Febriyanti RW, Lestari ES, Hadi P, Ciptaningtyas VR. Tuberkulosis Paru dengan Risiko Multi Drug Resistant di RS Rujukan Tertier di Jawa Tengah. Herb-Medicine J. 2021;4(2):61-67.
26. Shin S, Furin J, Ph D, et al. Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru. N Engl J Med. 2003;348(2):119-128.
2. World Health Organization. Drug Resistant TB. WHO. 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024/tb-disease-burden/1-3-drug-resistant-tb?
3. Ladha N, Bhardwaj P, Chauhan NK, Naveen KHS, Nag VL, Giribabu D. Determinants, risk factors and spatial analysis of multi-drug resistant pulmonary tuberculosis in Jodhpur, India. Monaldi Arch Chest Dis. 2022;92(4). doi:10.4081/monaldi.2022.2026
4. Abebe G, , Zegeye Bonsa WK. Treatment Outcomes and Associated Factors in Tuberculosis Patients at Jimma University Medical Center: A 5‑Year Retrospective Study Gemeda. Int J Mycobacteriology. 2017;6(3):239-245. doi:10.4103/ijmy.ijmy
5. de Dieu Longo J, Woromogo SH, Tekpa G, et al. Risk factors for multidrug-resistant tuberculosis in the Central African Republic: A case-control study. J Infect Public Health. 2023;16(9):1341-1345. doi:10.1016/j.jiph.2023.06.007
6. Ma JB, Zeng LC, Ren F, et al. Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study. Infect Drug Resist. 2022;15(August):4947-4957. doi:10.2147/IDR.S376177
7. Russom M, Tesfaselassie H, Goitom R, et al. Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study. Tuberc Res Treat. 2019;2019:1-6. doi:10.1155/2019/9429213
8. Baya B, Achenbach CJ, Kone B, et al. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Published online 2019:149-155. doi:10.1016/j.ijid.2019.02.004.Clinical
9. Saifullah A, Mallhi TH, Khan YH, et al. Evaluation of risk factors associated with the development of MDR-and XDR-TB in a tertiary care hospital: A retrospective cohort study. PeerJ. 2021;9:1-19. doi:10.7717/peerj.10826
10. Kizito E, Musaazi J, Mutesasira K, et al. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. BMC Infect Dis. 2021;21(1):1-7. doi:10.1186/s12879-021-05967-2
11. Elduma AH, Mansournia MA, Foroushani AR, et al. Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: A case-control study. Epidemiol Health. 2019;41:1-9. doi:10.4178/EPIH.E2019014
12. Admassu F, Abera E, Gizachew A, Sedoro T, Gari T. Risk factors of multidrug resistant tuberculosis among patients with tuberculosis at selected multidrug resistance treatment initiative centres in southern Ethiopia: A case-control study. BMJ Open. 2023;13(1):1-6. doi:10.1136/bmjopen-2022-061836
13. Tenzin C, Chansatitporn N, Dendup T, et al. Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: A nationwide case-control study. PLoS One. 2020;15(7 July):1-13. doi:10.1371/journal.pone.0236250
14. Soares VM, de Almeida IN, Figueredo LJ de A, et al. Factors associated with tuberculosis and multidrug-resistant tuberculosis in patients treated at a tertiary referral hospital in the state of Minas Gerais, Brazil. J Bras Pneumol. 2020;46(2):1-8. doi:10.36416/1806-3756/e20180386
15. Hirama T, Sabur N, Derkach P, et al. Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016. Canada Commun Dis Rep. 2020;46(04):84-92. doi:10.14745/ccdr.v46i04a05
16. Yao S, Yan J, Li L, et al. Determining mycobacterium tuberculosis drug resistance and risk factors for multidrugresistant tuberculosis in sputum smear-positive tuberculosis outpatients in Anhui province, China, 2015–2016. Infect Drug Resist. 2020;13:1023-1032. doi:10.2147/IDR.S244482
17. Wang Z, Hou Y, Guo T, et al. Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China. Front Public Heal. 2023;11. doi:10.3389/fpubh.2023.1117101
18. Camphor HS, Viney K, Polkinghorne B, Pennington K. Retrospective analysis of multidrug-resistant tuberculosis case notifications in Australia (1999-2018). Commun Dis Intell. 2020;44. doi:10.33321/cdi.2020.44.68
19. Carter BB, Zhang Y, Zou H, et al. Survival analysis of patients with tuberculosis and risk factors for multidrug-resistant tuberculosis in Monrovia, Liberia. PLoS One. 2021;16(4 April):1-13. doi:10.1371/journal.pone.0249474
20. Montalvo-Otivo R, Ramírez-Breña M, Bruno-Huamán A, Damián-Mucha M, Vilchez-Bravo S, Quisurco-Cárdenas M. Distribución geográfica y factores de riesgo de tuberculosis multidrogorresistente en el centro de Perú. Rev la Fac Med. 2020;68(2):245-251. doi:10.15446/revfacmed.v68n2.71715
21. Aderita NI, Murti B, Suryani N. Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Ngawi, Indonesia. J Epidemiol Public Heal. 2016;1(2):86-99.
22. Wotale TW, Lelisho ME, Negasa BW, Tareke SA, Gobena WE, Amesa EG. Identifying risk factors for recurrent multidrug resistant tuberculosis based on patient’s record data from 2016 to 2021: retrospective study. Sci Rep. 2024;14(1):23912. doi:10.1038/s41598-024-73209-x
23. Chuchottaworn C, Thanachartwet V, Sangsayunh P, et al. Risk factors for multidrug-resistant tuberculosis among patients with pulmonary tuberculosis at the central chest institute of Thailand. PLoS One. 2015;10(10):1-17. doi:10.1371/journal.pone.0139986
24. Afrina Y. Faktor Lingkungan Dengan Kejadian Tuberculosis Paru. J Ris Kesehat Poltekkes Depkes Bandung. 2023;15(1):1-21. file:///C:/Users/ACER/Downloads/2105-Article Text-8372-1-10-20230204.pdf
25. Febriyanti RW, Lestari ES, Hadi P, Ciptaningtyas VR. Tuberkulosis Paru dengan Risiko Multi Drug Resistant di RS Rujukan Tertier di Jawa Tengah. Herb-Medicine J. 2021;4(2):61-67.
26. Shin S, Furin J, Ph D, et al. Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru. N Engl J Med. 2003;348(2):119-128.
Authors
Azzahra, I. N. A., Adi, M. S., & Hadisaputro, S. (2025). FACTORS INFLUENCING THE DEVELOPMENT OF MULTI DRUG-RESISTANT TUBERCULOSIS: LITERATURE REVIEW. JURNAL RISET KESEHATAN POLTEKKES DEPKES BANDUNG, 17(2), 442–453. https://doi.org/10.34011/juriskesbdg.v17i2.2902
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.